• Brianna Henson, Hanna Hollingsworth, Erika Nevois, and Chris Herndon.
• Brianna Henson, PharmD, is with PGY-2 Pediatric Pharmacy Resident, Wake Forest Baptist Health Brenner Children's Hospital, Winston-Salem, North Carolina, USA; Hanna Hollingsworth, PharmD, BCPS, is with Pain Clinical Pharmacy Specialist, Parkland Health and Hospital System, Dallas, Texas, USA; Erika Nevois, PharmD, is with CVS/Pharmacy, Springfield, Illinois, USA; Chris Herndon, PharmD, BCACP, is with School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, Illinois, USA.
• J Pain Palliat Care Pharmacother. 2020 Mar 1; 34 (1): 22-31.

AbstractMigraine is highly prevalent and associated with a large socio-economic burden in the United States. Current preventive medications have variable efficacy and their use is often limited by intolerable side effects. Calcitonin gene-related peptide (CGRP) has been identified as an integral part of migraine pathophysiology. There are currently seven CGRP antagonists under investigation, all of which are undergoing or have completed phase 3 clinical trials. Three of the investigated CGRP antagonists are approved for use within and outside of the United States. The trials have resulted in positive efficacy and safety data. The purpose of this review is to evaluate the seven CGRP antagonists and their future place in therapy.

12 keywords...

hide…